MEKINIST Drug Patent Profile

When do Mekinist patents expire, and what generic alternatives are available?

Mekinist is a drug marketed by Novartis and is included in two NDAs. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and eight patent family members in forty-seven countries.

The generic ingredient in MEKINIST is trametinib dimethyl sulfoxide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the trametinib dimethyl sulfoxide profile page.

DrugPatentWatch^® Generic Entry Outlook for Mekinist

Mekinist was eligible for patent challenges on May 29, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 16, 2030. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for MEKINIST

International Patents:	208
US Patents:	8
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	92
Patent Applications:	6,631
Drug Prices:	Drug price information for MEKINIST
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MEKINIST
What excipients (inactive ingredients) are in MEKINIST?	MEKINIST excipients list
DailyMed Link:	MEKINIST at DailyMed

See drug prices for MEKINIST

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for MEKINIST

Constraining patent/regulatory exclusivity:

TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY

NDA:

217513

Dosage:

SOLUTION;ORAL

Constraining patent/regulatory exclusivity:

8,580,304*PED

NDA:

204114

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for MEKINIST

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Erasca, Inc.	Phase 1
Peter Hosein, MD	Phase 1
University of Miami Sylvester Comprehensive Cancer Center	Phase 1

See all MEKINIST clinical trials

Pharmacology for MEKINIST

Drug Class	Kinase Inhibitor
Mechanism of Action	Protein Kinase Inhibitors

Paragraph IV (Patent) Challenges for MEKINIST

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MEKINIST	Tablets	trametinib dimethyl sulfoxide	0.5 mg and 2 mg	204114	1	2023-09-28

US Patents and Regulatory Information for MEKINIST

MEKINIST is protected by eight US patents and five FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-003	May 29, 2013		RX	Yes	Yes
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-003	May 29, 2013		RX	Yes	Yes	8,580,304*PED				Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-002	May 29, 2013		DISCN	Yes	No
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-003	May 29, 2013		RX	Yes	Yes	9,155,706*PED				Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-002	May 29, 2013		DISCN	Yes	No
Novartis	MEKINIST	trametinib dimethyl sulfoxide	SOLUTION;ORAL	217513-001	Mar 16, 2023		RX	Yes	Yes	7,378,423*PED				Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-001	May 29, 2013		RX	Yes	No

International Patents for MEKINIST

When does loss-of-exclusivity occur for MEKINIST?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MEKINIST around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2013313050
Australia	2016244279
Brazil	112015004578
Canada	2882437
China	104582706
China	107308164
Cyprus	1124812

Supplementary Protection Certificates for MEKINIST

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1761528	C300701	Netherlands		PRODUCT NAME: TRAMETINIB, DESGEWENST IN DE VORM VAN EEN FRAMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT OF SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/14/931/01-06 20140702
1761528	PA2014039	Lithuania		PRODUCT NAME: TRAMETINIBUM; REGISTRATION NO/DATE: EU/1/14/931/01-06 20140630
1761528	CA 2014 00055	Denmark		PRODUCT NAME: TRAMETINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HYDRAT ELLER SOLVAT DERAF, HERUNDER TRAMETINIBDIMETHYLSULFOXID; REG. NO/DATE: EU/1/14/931/01-06 20140630
1761528	14C0083	France		PRODUCT NAME: TRAMETINIB,EVENTUELLEMENT SOUS LA FORME D'UN SEL,HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/931 20140630
1761528	C20140036 00120	Estonia		CHANGE OF OWNER'S ADDRESS
1761528	1490063-3	Sweden		PRODUCT NAME: TRAMETINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF; REG. NO/DATE: EU/1/14/931 20140702
1761528	205 5032-2014	Slovakia		PRODUCT NAME: TRAMETINIB, PRIPADNE VO FORME JEHO FARMACEUTICKY PRIJATELNEJ SOLI, HYDRATU ALEBO SOLVATU; REGISTRATION NO/DATE: EU/1/14/931 20140702

Mekinist (trametinib) Market Dynamics and Financial Trajectory: Sales Trends, Pricing Pressure, Patent Cliff Risk, and Competitive Threats

Last updated: June 12, 2026

Mekinist (trametinib) is a targeted oral therapy in oncology that has faced a mature-market profile, with revenue driven by combination use (most notably with dabrafenib) and constrained by patent-expiration and competitive displacement risk. Financial trajectory is dominated by (1) BRAFV600E and NSCLC line-of-therapy positioning, (2) payer uptake dynamics for combination regimens, (3) generic and biosimilar substitution risk tied to exclusivity and patent estate structure, and (4) competition from newer BRAF/MEK combinations and third-generation or next-line targeted standards that reduce incremental TAM.

---

How has Mekinist’s revenue trajectory evolved since launch?

Short answer: Mekinist revenue has followed a typical targeted-therapy curve: launch growth on BRAFV600E-driven indications, peak during period of broad payer uptake for combination regimens, and subsequent deceleration as exclusivity aged, competing regimens gained share, and later-line treatment patterns tightened.

Key demand drivers that historically supported sales

• Combination standard-of-care: Mekinist is most consistently used with dabrafenib in BRAFV600E-mutant melanoma and other specified settings. Combination regimens create “bundle economics” that lift MEK uptake beyond what monotherapy could achieve.
• Label breadth across tumor types: Trametinib’s commercial demand is tied to expanded clinical positioning beyond melanoma into BRAFV600E-mutant contexts that remain under targeted pathways.
• Payer coverage anchored to response metrics: Uptake is governed by plan formularies and prior authorization requirements that weigh response and survival endpoints versus cost.

Key demand constraints that shaped later growth

• Therapy-line compression: As newer sequencing strategies emerge, MEK inhibitor share can shift toward regimens used earlier or toward alternatives that change selection criteria.
• In-market competition from next-generation targeted options: Expanding therapeutic alternatives reduce incremental patient starts even when overall BRAF/MEK class demand remains stable.
• Patent aging and price erosion: Even without immediate generic substitution, pricing pressure typically appears before legal expiration through negotiated rebates, reference pricing, and payer tiering.

---

What market dynamics determine Mekinist’s current demand and pricing power?

Short answer: Mekinist demand is determined by regimen selection within BRAF/MEK standards, payer restrictions that govern combination starts, and the rate at which prescribers shift toward competing targeted or immunotherapy sequencing.

Payer and channel dynamics

• Formulary placement: Targeted oncology products often face step edits and prior authorization tied to biomarker confirmation (eg, BRAF mutation testing).
• Combination access rules: Plans may require defined criteria for using Mekinist with dabrafenib, limiting use when patients fall outside pre-set response, staging, or treatment history.
• Rebate pressure as portfolio ages: As products mature, net pricing depends more on contracting than on list price.

Prescriber adoption and real-world utilization

• Biomarker prevalence sensitivity: Demand tracks BRAFV600E testing penetration and eligibility.
• Toxicity management economics: Real-world dosing and discontinuation due to adverse events can reduce duration-of-therapy, which lowers prescription-based revenue even if patient numbers are stable.

---

Which indications drive Mekinist sales, and how do they affect growth vs decline?

Short answer: Trametinib’s commercial base is strongest in BRAFV600E-mutant settings where combination therapy is entrenched, and it softens as competition shifts patient selection in later lines.

Melanoma and combination dependence

• Mekinist sales are tightly linked to BRAFV600E/K-mutant melanoma utilization, where the dabrafenib-trametinib combination is a key driver.

Other tumor contexts

• Trametinib also participates in broader oncology treatment strategies where targeted selection depends on molecular testing availability and guideline alignment.

---

How does Mekinist’s revenue depend on combination therapy with dabrafenib?

Short answer: Mekinist’s financial profile is structurally linked to dabrafenib utilization because the combination forms the core commercial regimen. Any shift in dabrafenib prescribing, access, or sequencing shifts Mekinist starts.

Implications for budgeting and licensing

• Cross-product risk: If dabrafenib adoption declines due to competitive regimens or adverse-event profiles, Mekinist volume typically falls proportionally.
• Contracting leverage: Combination contracting can reduce payer willingness to switch components separately, slowing displacement but increasing rebate pressure as negotiation expands.

---

What patents protect Mekinist, and when does exclusivity end?

Short answer: Exclusivity and patent life determine generic entry timing and price erosion. Mekinist’s market dynamics are influenced by the expiration schedule of composition-of-matter, formulation, and use patents, plus any market exclusivity attached to approved indications.

Patent estate components that impact entry risk

• Composition-of-matter patents: Set baseline protection for the active pharmaceutical ingredient (API).
• Formulation and dosage patents: Delay “authorized generic” style entry for specific dosage forms or stability/absorption improvements.
• Method-of-use and combination patents: Govern life-cycle protection around specific regimens such as dabrafenib-trametinib combinations in labeled populations.

Generic entry scenario mechanics

• Even if composition-of-matter expires, generic launch can be blocked by:
  • still-active method-of-use claims
  • formulation-specific patents
  • extension-like exclusivities or regulatory exclusivity windows
  • settlement agreements that delay launch

(Patent numbers, expiration dates, and Orange Book entries are required for a complete, litigation-grade exclusivity map, but are not provided in the available input.)

---

What generic entry risks exist for Mekinist?

Short answer: Generic risk is mostly a timing and litigation-path issue: Paragraph IV challenges and settlement terms decide whether launch is early, blocked, or delayed.

Key risk vectors

• Paragraph IV filing probability: In mature targeted oncology categories, generic challengers frequently file once a viable claim is identified for challenge.
• Injunction and 30-month stay: If the ANDA is tied to a successful market-entry challenge, legal stays can delay generic launch even after a filing.
• Design-around: Competitors can attempt to avoid formulation claims through alternate manufacturing or bioequivalent approaches if allowed.

Commercial impact of first-wave generic entry

• Launch tends to trigger:
  • immediate net price compression via wholesale acquisition cost discounting
  • rapid reimbursement recalibration in managed care
  • volume switch toward lower-cost alternatives once switching thresholds are met

(Quantified entry timing requires Orange Book and patent litigation data.)

---

What patent litigation affects Mekinist, and how do settlements shift launch timing?

Short answer: For an aging targeted oncology product, patent litigation and settlements can materially affect generic and authorized generic launch timelines, which directly changes revenue and net pricing.

What to track in Mekinist-specific litigation

• Court dockets and asserted claims: Identify which patents are actually in play (composition, formulation, or method-of-use).
• Injunction posture: Whether courts block entry pending final adjudication.
• Settlement scope: Whether a settlement includes:
  • pay-for-delay style terms
  • “carve-out” for specific indications
  • delayed launch dates and agreed labeling restrictions

(No litigation docket specifics were provided in the available input.)

---

What is the Orange Book status of Mekinist?

Short answer: Orange Book status determines whether ANDAs can reference listed patents and what is still listed for the drug product and route.

What the Orange Book map typically shows

• Listed patents by:
  • submission date
  • expiration date
  • claims types (including method-of-use)
• Regulatory exclusivities such as:
  • non-patent exclusivities
  • additional exclusivities tied to indications

(Orange Book listing details were not provided in the available input.)

---

How strong is the patent estate for trametinib compared with other MEK inhibitors?

Short answer: In MEK inhibitor classes, estate strength typically depends on how broadly the company holds combination and method-of-use coverage and whether formulation and dosing patents prevent straightforward generic substitution.

Competitive comparison framework

• Claim breadth: Coverage of combination regimens and biomarker-defined subpopulations.
• Residual claims near expiration: Patent density in the final 2 to 5 years of life.
• Likelihood of generic design-around: Formulation-specific and dosing-step claims can raise technical/IP barriers.

(A comparative assessment requires specific Mekinist patents and competitor patent estates.)

---

How does Mekinist compare with competing BRAF/MEK or targeted regimens on market outcomes?

Short answer: Competitive displacement is driven by clinical preference, tolerability, and sequencing guideline uptake. If competing regimens deliver similar outcomes with better convenience or lower discontinuation rates, Mekinist volume can decline even if overall class demand remains stable.

Where displacement usually shows up first

• First-line or earlier-line selection shifts away from MEK inhibitor-containing regimens.
• Guideline revisions reduce patient eligibility for combinations.
• Payer step-editing encourages preferred products.

(Competitor selection and relative market share quantification requires specific drug roster and commercial data not provided in the available input.)

---

What does Mekinist’s financial performance imply for future profitability and pipeline reinvestment?

Short answer: A mature targeted oncology product that faces rising pricing pressure and possible legal entry risks tends to show margin compression unless offset by contracting leverage, indication growth, or new regimen data. Profitability then depends on maintaining net pricing and sustaining patient starts.

Profit drivers

• Net price vs list: Negotiated rebates and managed care discounts increasingly determine realized revenue.
• Duration of therapy: Toxicity management and adherence affect paid prescription volume.
• Mix shift: Higher-value combinations support better contracting economics.

Risk drivers

• Patent expiration and generic substitution: Primary driver of step-down revenue.
• TAM saturation: Declining incremental eligible population.
• Competitive regimen preference: Uptake shifts toward better-tolerated or more convenient standards.

---

Key Takeaways

• Mekinist revenue is anchored to trametinib’s combination role in biomarker-defined oncology populations, especially where dabrafenib-trametinib is a standard regimen.
• Market dynamics increasingly hinge on payer contracting, sequencing behavior, and real-world tolerability, which affect both starts and duration of therapy.
• Financial trajectory typically shifts from growth to maturity as patents age, with net price erosion appearing before any potential generic launch.
• The magnitude and timing of future revenue risk depend on exact Orange Book listings, patent expiration schedule, and litigation or settlement terms, which govern generic entry and price compression.

---

FAQs

1. How do prior authorization criteria affect Mekinist prescription volume?
   They restrict use to biomarker-confirmed and label-eligible patients, reducing non-adherent starts and impacting real-world treatment initiation.

2. Does Mekinist revenue track melanoma incidence or biomarker testing rates more closely?
   It tracks both, with biomarker testing penetration often determining the portion of eligible patients that can access therapy.

3. What combination sequencing changes most often reduce Mekinist utilization?
   Shifts toward regimens used earlier or toward alternatives with better real-world tolerability reduce new starts for MEK inhibitor-containing combinations.

4. How does patent estate structure change generic entry risk for oncology tablets?
   Combination and method-of-use claims can delay ANDA launches even after composition-of-matter expiration.

5. What commercial metrics best predict Mekinist net sales trend?
   Managed care net price, patient starts, treatment duration (discontinuation rates), and rebate trajectory.

---

References

1. FDA Orange Book (Drug Products, Including Combination Drug Products). U.S. Food and Drug Administration.
2. FDA Drug Label for Mekinist (trametinib). U.S. Food and Drug Administration.

DrugChatter Q&A for MEKINIST

When will generic MEKINIST launch?